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ABSTRACT
Objectives:
The objective of this study was to determine the frequency of non-motor symptoms (NMS) in patients with Parkinson's
disease (PD) and to compare frequency in mild and severe disease. Materials and methods: This descriptive
observational study was done from January 2015 to June 2015 at Department of Neurology, Pakistan Institute of
Medical Sciences, Islamabad. We used Non-Motor Symptom Questionnaire (NMS-Q); a validated scale using 30
questions related to 9 different domains of symptoms. Results: 62 patients were enrolled in the final data set of study
(male 46, Female 16) with average age of 62.4 years (range=33-80). Non-motor symptoms were reported very
commonly in all stages of PD including urinary urgency (74%), dizziness (71%), memory problems (71%), sexual
difficulty (69%), constipation (67%) and depression (62%). Only non-motor symptom that was statistically significantly
higher in the severe stages was “reported falls” (Mild 39%, severe 61%, p < 0.01). Some were more common
(lightheadedness, falls, sexual difficulty) while others were less (hyposmia). Conclusion: Non-motor symptoms are
very common in Pakistani population of PD and are seen equally in mild and severe PD with exception of “reported
falls”. The high prevalence of non-motor symptoms (especially in mild stages) should be kept in mind while managing
PD. Furthermore, there may be the likely need for a culturally appropriate screening scale for our population.
Keywords:
Parkinson Disease, Non-motor symptoms, Pakistani population, NMS-Q, falls.

INTRODUCTION

been recognized over the years in PD including
symptoms of gastrointestinal system, urinary system,
sleep disturbance, psychiatric, sensory and cognitive
impairment.5 The exact etiology has not been fully
elucidated but there is evidence of involvement of
non-dopaminergic pathways (such as cholinergic and
serotonergic). Non-motor symptoms often precede
motor symptoms by up to several decades, most
commonly olfactory dysfunction (hyposmia), Rapid Eye
Movement (REM) sleep behavior disorder (RBD),
constipation, depression, and pain.6 Non-motor
symptoms may be classified based on neurotransmitter
pathways involved however most of them involve wide
spread connections within the brain and thus hard to
be classified separately. The non- motor symptoms are
an integral part of the disease but are generally under
recognized by the treating physician and under reported
by the patients. Assessment of non-motor symptoms

Parkinson's (PD) is the second most common
neurodegenerative disorder. Its risk increases with
advancing age. Parkinson’s Disease has been known
since ancient times with the earliest mention in Indian
medical manuscripts Ayeur Veda around 1000BC as
“Kampavata.” 1, 2 It was named after James Parkinson
who wrote a detailed monograph titled “an easy on
shaking palsy” in 1817. 2, 3 European PD association
estimates prevalence of PD as 6.3 million worldwide,
affecting all races and cultures. Prevalence in Pakistan
has been estimated to be 0.4 million by Pakistan
Parkinson Disease Society. 4
Since its first description to until recently, it’s been
largely dealt as a motor disease involving dopaminergic
deficit. However various non-motor symptoms have
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should be a part of management of PD and there are
many validated tools available such as Non-Motor
Symptom
Questionnaire
(NMSQ),
Non-motor
Symptoms Survey (NMSS),EQ -5D, Parkinson Disease
Questionnaire(PDQ)39.7

Figure 1: Hoehn &Yahr Scale of PD
STAGIN
NG OF PD – H
HOEHN & YA
AHR SCALE

The frequency of non-motor symptoms in Pakistani PD
population is not known (though assumed to be similar
to western population). The non-motor symptoms are
also considered to be a problem of severe disease and
thus routinely ignored in early disease by practicing
physicians. In this study we intended to find the
frequency of non-motor symptoms in Parkinson’s
Disease and compare frequency between mild and
severe disease.8,9
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Statistical Analysis

MATERIALS AND METHODS

Data was analysed through SPSS version 17. The
numerical data was expressed as mean and standard
deviation (SD). The categorical data was expressed as
frequency and percentages. Pearson’s Chi square test
was used to compare the frequency of NMS in mild and
severe disease. A p-value of less than 0.05 was
considered statistically significant.

This study was a cross-sectional, observational,
descriptive study; carried out on population of PD
patients presenting to Outpatient clinics at Department
of Neurology, Pakistan Institute of Medical Sciences
(PIMS), Islamabad (a Tertiary Care Center). This study
was internally funded and approved by the local ethics
committee in accordance with Declaration of Helsinki.

RESULTS
Statistical Analysis

All the patients who full-filled the clinical criteria of
Parkinson’s Disease were included in the study
according to UK Brain Bank Criteria (Annexure I).10
Other inclusion parameters were age ≥ 18 years, able
to give consent and able to answer questions
independently or with help. Exclusion criteria were
concern for atypical Parkinson’s, history of psychiatric
disease or co-morbid conditions that could contribute
to NMS like diabetes mellitus. Mild Parkinson’s Disease
was defined as stage I&II of Hoehn and Yahr scale while
severe disease was defined as stage III, IV & V of Hoehn
and Yahr scale.11 Informed consent was obtained from
the patients. The data was recorded with following
variables: demographic details; age and gender, staging
of Parkinson’s Disease according to Hoehn and Yahr
Scale (Figure 1). We used Non-Motor Symptom
Questionnaire (NMS-Q); a validated scale using 30
questions related to 9 different domains of symptoms
(Annexure II).

Data was analysed through SPSS version 17. The
numerical data was expressed as mean and standard
deviation (SD). The categorical data was expressed as
frequency and percentages. Pearson’s Chi square test
was used to compare the frequency of NMS in mild and
severe disease. A p-value of less than 0.05 was
considered statistically significant.
RESULTS
Over the course of the study, 81 patients were
screened. Those fulfilling the criteria for the study were
included in the final data set. A total of 62 patients with
Parkinson’s Disease were recruited over 6 months
period. The average age was 62.4 ± 11.57 years with
youngest being 33 years and oldest 80 years of age.
Males were more common (n=46, 74.1%) then
females (n=16, 25.8%) with a ration of 3:1.
13 Patients were aged less than 60 (young onset PD)
including 3 patients in stages II and IV each and 7 in
stage III. No patient was seen in stage I (likely cultural
bias, as very early PD does not seek treatment
potentially from lack of awareness and other
differences). Majority of patients were above age 60
(n=49) and had relatively milder disease (59% in stage

The NMS-Q was filled by the patient either
independently or assisted by family member(s). Where
there was language problem, the author helped in
translating the questionnaire to the patient.10
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I & II) compared to younger population. None were
seen in Stage 5. Similarly, looking at Stage distribution
between males and females, males were
proportionately more in mild disease (Stage I & II) in
comparison with females (males 60%, females 25%)
(Figure 2 & 3).

significantly high frequency with difficulty staying asleep
being 58.1% and Restless Leg Syndrome being 59.7%,
while unexplained pains and unexplained weight
change were reported to be 61.3% and 38.7%
respectively. Symptoms like dribbling saliva, double
vision, dysphagia and hyposmia were in frequency of
32.3%, 29%, 35.5% and 37.1% respectively. The p
value was only significant for falling (p<0.01) when
comparison was done between frequency of non-motor
symptoms for mild and severe Parkinson’s Disease. The
complete list of questions asked and frequency of
symptoms is listed in Table 1.

Figure 2: Stages of PD with age distribution
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Table 1. Frequency of Non-Motor Symptoms
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Figure 3: Gender Distribution of severity of PD
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The urinary symptoms (urgency and nocturia) were
most frequent (74.1% and 51.6% respectively) (see
Table1). The gastro-intestinal symptoms were next in
frequency with constipation being most common at
67.7%. Neuropsychiatric symptoms were considerably
high, including memory problems, low mood, anxiety
and abnormal libido (71%, 62.9%, 51.6%, 67.7% in
respective order). Autonomic symptoms like feeling
light-headed and falling as a result were common (71%
and 66.1%) while swelling of legs was uncommon at
29%. Difficulty in performing sex was reported by
67.7%. The sleep related problems also showed
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All patients

Urinary Urgency

46 (74.1)

Mild PD
(I/ II)
25 (54.3)

Nocturia

32 (51.6)

14 (43.7)

Severe PD
(III/ IV)
21 (45.7)

p value
0.46

18 (56.2)

0.54

Hyposmia

23 (37.1)

13 (56.5)

10 (43.5)

0.55

Dysphagia

22 (35.5)

13 (59.1)

09 (40.9)

0.38

Nausea/ vomiting

06 (9.7)

04 (66.7)

02 (33.3)

0.43

Constipation

42 (67.7)

24 (57.1)

18 (42.9)

0.20

Incontinence

18 (29.0)

08 (44.4)

10 (55.6)

0.47

Tenesmus

27 (43.5)

13 (48.1)

14 (51.9)

0.63

Memory impairment

44 (71.0)

24 (54.5)

20 (45.5)

0.47

Loss of interest

25 (40.3)

14 (56.0)

11 (44.0)

0.57

Hallucinations

23 (37.1)

15 (65.2)

8 (34.8)

0.10

Loss of concentration

25 (40.3)

15 (60.0)

10 (40.0)

0.27

Low mood

39 (62.9)

21 (53.8)

18 (46.2)

0.64

Anxiety

32 (51.6)

15 (46.9)

17 (53.1)

0.44

Libido

42 (67.7)

21 (50.0)

21 (50.0)

0.71

Sexual dysfunction

43 (69.4)

20 (46.5)

23 (53.5)

0.22

Delusions

20 (32.3)

09 (45.0)

11 (55.0)

0.47

Somnolence

23 (37.1)

12 (52.2)

11 (47.8)

0.94

Insomnia

36 (58.1)

17 (47.2)

19 (52.8)

0.41

Nightmares

26 (41.9)

14 (53.8)

12 (46.2)

0.76

Parasomnia

22 (35.5)

12 (54.5)

10 (45.5)

0.73

Restless legs

37 (59.7)

16 (43.2)

21 (56.8)

0.10

Orthostatic hypotension

44 (71.0)

21 (47.7)

23 (52.3)

0.33

Falls

41 (66.1)

16 (39.0)

25 (61.0)

<0.01*

Pedal edema

18 (29.0)

10 (55.6)

08 (44.4)

0.69

Excessive sweating

23 (37.1)

14 (60.9)

09 (39.1)

0.26

Double vision

18 (29.0)

08 (44.4)

10 (55.6)

0.47

Unexplained pains

38 (61.3)

19 (50.0)

19 (50.0)

0.74

Weight change

24 (38.7)

09 (37.5)

15 (62.5)

0.07

Drooling

20 (32.3)

10 (50.0)

10 (50.0)

0.86

DISCUSSION
In this study we highlight the overall high frequency of
NMS in PD in Pakistani population, and their
comparison between mild and severe disease. Some of
the components differ in frequency compared to other
studies carried out around the world which will be
discussed below.
In our study the highest overall NMS was found to be
urinary urgency at 74%, comparatively higher than
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other studies. Bonnet et al. in 2012 described the
urinary urgency in more than 50% of patients and Khoo
et al. described urinary urgency in spectrum of NMS in
Early PD at 46 %.6, 10 Constipation was the next
frequent NMS found in this study at 67.7%. This was
higher than study of Bonnet et al (45 to 60%), but
similar to studies by Khoo et al (67%) and Azmin et al
(67%) who looked at Malaysian population.6, 10, 11
There was no significant difference between mild versus
severe disease in our study; however study carried out
in Italy (PRIAMO), constipation was found to be lower in
Stage 1 (37%) and much higher in Stage 5 (73%). The
constipation is treated in PD in usual manner like
avoiding dehydration, use of laxatives and judicious use
of fiber. 11

headed and dizziness) were present in 71%, and falling
was also common at 66.1%. The incidence of these
symptoms was extremely low in PRIAMO study (14.2%
and 1% respectively).12 Khoo et al. reported somewhat
higher number but still lower than our population (33%
and 23% respectively).10 Sleep related problems
(insomnia and Restless Leg Syndrome (RLS) were
present in frequency of 58.1% and 59.7% (Table 1)
with no difference in mild and severe disease (p 0.1
and 0.4 respectively). This is similar to some studies
such as study in Norwegian population reported
incidence of sleep problems to be 60%.17,18 Another
study by Prudon et al. looking at primary sleep disorder
prevalence in patients with newly diagnosed
Parkinson's disease reported similar results.19

Neuropsychiatric symptoms (low mood and memory
impairment) involve cholinergic pathways and may
predate onset of clinical PD with motor symptoms.8, 9, 10,
11, 12
We found neuropsychiatric symptoms like
forgetting things and low mood was common (71% and
62% respectively), with no significant difference
between mild and severe disease (p 0.47 and 0.6
respectively) (Table 1). Other studies have reported
slightly lower incidences of 53-67%.9, 10, 11, 12 The
dopamine effect is variable on psychiatric domain, with
some patients responding positively while in others the
effect remains unpredictable. Depression is linked with
mortality and morbidity.12, 13, 14 It needs to be addressed
properly at every stage of Parkinson’s disease and
should be treated aggressively.

The prevalence of self-reported hyposmia was only
23%. This is in contrast to other studies which report
this finding to be almost universal such as Xiao et al.
described its prevalence of almost 90% while another
study by Haehner reported it to be 95%.20, 21 This gross
difference in the prevalence can be explained by the
fact that simple question may not reveal the underlying
problem unless tested by specific kits.21 Since
hyposmia in recent trials has been shown to be a
predictor of PD as well as dementia, it suggests a need
for a better designed screening question for hyposmia
as it pertains to our population to carry out further
research in our population. 22, 23, 24
Our study had some limitations including gender bias
with males being more common than females (ratio
3:1), slightly more than western population (2:1) and
likely represent culture bias (men more likely to seek
treatment). Similarly, we noticed men to be in relatively
milder disease compared with females. This may
represent a treatment bias (where females are less
likely to take medications or seek early treatment) and
may also represent less access to healthcare by
females (considered at-risk population). We also used
a questionnaire not designed or validated in our
population due to lack of such. The study population
was small number and having a single site may have
resulted in selection bias (studying only patients
presenting to our hospital).

Sexual problems were also reported very high in our
cohort in the form of decreased libido (67.7%) and
difficulty in performance (69.4%) with no difference in
frequency between mild and severe (p 0.7 and 0.2
respectively) (Table 1). According to Bronner et al., the
sex problems correlated more with severity of motor
disease and male gender compared with age,
depression and use of L-dopa.15 Khoo et al. reported
significantly lower incidence of impaired libido and
sexual dysfunction (17% and 28% respectively).10
Similarly Azmin et al. reported it to be only 8%.11 One
explanation of such marked difference could be
different culture and social norms and biases against
reporting. It is pertinent that this topic should be
approached with due respect with the patient and
managed appropriately.16

CONCLUSION
We have shown that non-motor symptoms are
extremely common in Parkinson’s disease in Pakistani
population and the frequency of symptoms is similar in
mild and severe disease except for frequent falls (more
common in severe Disease)."This is in contrast to
findings in other population groups with many

Among all the NMS, incidence of falling was the only
reported symptom that was statistically significant (p<
0.01) between mild and severe disease in our study.
Fear of falling has been shown to be directly related to
actual falling.16 Orthostatic hypotension (feeling light
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symptoms being much more common in our population
(such as orthostatic hypotension and falls). Others are
either lower or more difficult to screen (such as
hyposmia)." This highlights the strong need for larger
scale studies to understand the incidence and the likely
need for a culturally appropriate screening scale for our
population.
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